These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1726013)

  • 1. Antiatherogenic properties of calcium antagonists.
    Bond MG; Purvis C; Mercuri M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S87-92; discussion S92-3. PubMed ID: 1726013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of calcium antagonists on atherosclerosis progression and intima media thickness].
    Zannad F
    Drugs; 2000; 59 Spec No 2():39-46. PubMed ID: 11002857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventional clinical trials using noninvasive ultrasound end points: the Multicenter Isradipine/Diuretic Atherosclerosis Study. The MIDAS Research Group.
    Bond MG; Strickland HL; Wilmoth SK; Safrit A; Phillips R; Szostak L
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S30-3. PubMed ID: 1695299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel blockers and atherosclerosis.
    Henry PD
    J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S12-5. PubMed ID: 1706008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel blockers and atherosclerosis.
    Sowers JR
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):3-9. PubMed ID: 2220798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium antagonists and atherosclerosis.
    Betz E; Weiss HD; Heinle H; Fotev Z
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S71-5. PubMed ID: 1725009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiatherosclerotic effects of calcium antagonists.
    Paoletti R; Bernini F; Corsini A; Soma MR
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S6-10. PubMed ID: 8852538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter study with isradipine and diuretics against atherosclerosis. US MIDAS Research Group.
    Borhani NO; Brugger SB; Byington RP
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S23-9. PubMed ID: 1695298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcium antagonists and development of the atheromatous plaque].
    Weber S
    Arch Mal Coeur Vaiss; 1997 May; 90 Spec No 2():51-3. PubMed ID: 9295927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of calcium antagonists and atherosclerosis.
    Keogh AM; Schroeder JS
    J Cardiovasc Pharmacol; 1990; 16 Suppl 6():S28-35. PubMed ID: 1707112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of calcium antagonists in the treatment of atherosclerosis and hypertension.
    Ouchi Y; Orimo H
    J Cardiovasc Pharmacol; 1990; 16 Suppl 2():S1-4. PubMed ID: 1369701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atheroma and calcium antagonists].
    Lechat P; Hadjiisky P
    Therapie; 1993; 48 Spec No():665-70. PubMed ID: 8091352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
    Hof RP; Rüegg UT
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):107S-113S. PubMed ID: 1826999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells.
    Orekhov AN; Baldenkov GN; Tertov VV; Ryong LH; Kozlov SG; Lyakishev AA; Tkachuk VA; Ruda MYa ; Smirnov VN
    J Cardiovasc Pharmacol; 1988; 12 Suppl 6():S66-8. PubMed ID: 2468911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockers, plasma lipids, and coronary heart disease.
    Cruickshank JM
    Circulation; 1990 Sep; 82(3 Suppl):II60-5. PubMed ID: 1975524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiatherogenic properties of calcium antagonists. State of the art.
    Weinstein DB; Heider JG
    Am J Med; 1989 Apr; 86(4A):27-32. PubMed ID: 2653028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-atherosclerotic action of hypotensive drugs].
    Gmiński J; Stajszczyk M
    Wiad Lek; 1996; 49(7-12):182-98. PubMed ID: 9245114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of various calcium antagonists against experimental arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Fleckenstein A
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S13-8. PubMed ID: 1293304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modification of coronary arteriosclerosis in man by calcium antagonists?].
    Schneider W; Roebruck P; Cieslinski G; Noack H; Kober G; Alle M; Kaltenbach M
    Z Kardiol; 1991; 80 Suppl 9():63-71. PubMed ID: 1796651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.